atepeq/tico19 huggingface dataset:
Thus, administration of type I interferon at least in the early phase of SARS-CoV-2 infection in humans should be beneficial.
Don haka, gudanar da nau'in I interferon aƙalla a farkon kamuwa da cutar SARS-CoV-2 a cikin ɗan adam ya kamata ya zama da amfani.
In addition, NLRP3 inflammasome activation in bats is defective.
Bugu da Kari, kunnawar NLRP3 cikin jemagu na da illa.
By this reasoning, inhibition of NLRP3 inflammasome with MCC950 might be useful in the treatment of COVID-19.
Lura da wannan dalilin, rayuwar kwayar halittar NLRP3 da kumburinsa da MCC950 zai yi tasiri wajen warkar cutar COVID-19.
The emergence of SARS-CoV-2 follows the general theme by which SARS-CoV and MERS-CoV arose.
Samuwar SARS-CoV-2 ya biyo bayan jigo ne wanda SARS-CoV da MERS-CoV suka tashi.
Whereas a bat beta-CoV sharing 95% nucleotide homology with SARS-CoV has been found, there also exists a bat-CoV sharing 96% nucleotide homology with SARS-CoV-2.
Ganin cewa wata beta-CoV raba 95% nucleotide homology tare da SARS-CoV, Hakanan akwai wanzuwar batirin-CoV wanda ke hade da kashi 96% na nucleotide homology tare da SARS-CoV-2.
Whereas civets and other animals in the markets have been found to harbour viruses identical to SARS-CoV, immediate intermediate hosts for SARS-CoV-2 have not been identified.
Ganin cewa dabbar sivets da sauran dabbobi a cikin kasuwanni an same su dauke da ƙwayoyin cuta masu kama da SARS-CoV, ba a gano mafakar SARS-CoV-2 ta nan-kusa ba.
Pangolin beta-CoVs strikingly homologous to SARS-CoV-2 have been found, indicating that pangolins might serve as one of intermediate hosts or pangolin beta-CoVs could contribute gene fragments to the final version of SARS-CoV-2.
Pangolin beta-CoVs mai matukar alaƙar daidaituwa ga SARS-CoV-2 an samo, yana nuna cewa pangolins na iya zama ɗaya daga cikin tsaka-tsakin runduna ko pangolin beta-CoVs na iya ba da gudummawar gutsuttsuran jabu ga fasalin ƙarshe na SARS-CoV-2.
Although questions remain, there is no evidence that SARS-CoV-2 is man-made either deliberately or accidentally.
Kodayake tambayoyin suna wanzuwa, babu wata shaida da ke nuna cewa SARS-CoV-2 an yi mutum ne da gangan ko hadari.
CoVs have returned to the limelight due to the recent outbreak of SARS-CoV-2.
CoVs sun dawo zuwa haskakawa sakamakon barkewar kwanan nan na SARS-CoV-2.
The study of CoVs in bats and other animals has drastically changed our perception of the importance of zoonotic origins and animal reservoirs of HCoVs in human transmission.
Nazarin cututtukan CoVs a jikin jemagu da sauran dabbobi ya sauya tunaninmu game da muhimmancin tushen cutar HcoVs ta samo asali ne daga jikin dabbobi wajen baza ta zuwa ga mutane.
Pervasive evidence has shown that SARS-CoV, MERS-CoV and SARS-CoV-2 have a bat origin and are transmitted to humans via intermediate hosts.
Shaida da yawa ta nuna cewa SARS-CoV, MERS-CoV da SARS-CoV-2 suna da asalin batir kuma ana tura su ga mutane ta hanyar runduna ta tsakiya.
Given that SARS-CoV infection originates from the contact between humans and civets in the markets, closing wet markets and killing civets therein could have effectively ended the SARS epidemic.
Ganin cewa cutar SARS-CoV ta samo asali ne daga saduwa tsakanin mutane dabbar civets a cikin kasuwanni, rufe kasuwannin rigar da kashe biranen da ke faruwa na iya kawo karshen cutar ta SARS.
By the same reasoning, pangolins should be removed from wet markets to prevent zoonotic transmission, in view of the discovery of multiple lineages of pangolin beta-CoVs closely related to SARS-CoV-2.
Ta hanyar dalilai iri ɗaya, ya kamata a cire pangolins daga kasuwannin nama don hana watsa cuta daga dabba zuwa mutum, ta la'akari da binciken gano asalin cutar a pangolin da yawa daga beta-CoVs masu kusancin dangantaka da SARS-CoV-2.
However, whether and how SARS-CoV-2 is transmitted to humans through pangolins and other mammals remain to be clarified in future investigations.
Koyaya, ko yaya kuma aka watsa SARS-CoV-2 ga mutane ta hanyar pangolins da sauran dabbobi masu shayarwa har yanzu za'a fayyace su a cikin binciken da za'a yi nan gaba.
On the other hand, MERS-CoV has existed in dromedary camels for a long time.
A gefe guda, MERS-CoV ya wanzu cikin rakuman larabawa.
These camels serve as an important tool for transportation as well as a main source of meat, milk, leather and wool products for the local people.
Waɗannan raƙuma suna da mahimmanci ga kayan sufuri da kuma babban tushen nama, madara, fata da kayan ulu ga mutanen yankin.
They are widely distributed across the Middle East and Africa.
Suna nan ko ina a Gabas ta Tsakiya da Afirka.
It is therefore impossible to sacrifice all camels for the control of MERS, as what was done in wild animal markets in China to prevent the spreading of SARS-CoV and SARS-CoV-2.
Don haka, kusan abune da ba zai yiwuwa ba a ce a soke dukkan rakuma domin kawai a shawo kan cutar ta MERS, kamar dai yadda aka yi a kasuwar dabbobin dawa a qasar China domin shawo kan bazuwar cutar SARS-CoV da SARS-CoV-2.
To stop the recurrent outbreaks of MERS, a comprehensive approach should be taken to develop effective vaccines against MERS-CoV for camels, in combination with other infection control measures.
Don dakatar da yawan yaduwar MERS, ya kamata a ɗauki cikakkiyar hanya don haɓaka rigakafin tasiri ga MERS-CoV don raƙuma, tare da sauran matakan kula da kamuwa da cuta.
As we are not able to eliminate these viruses, new genotypes might emerge to cause outbreaks.
Kasancewar ba mu iya kawar da kwayoyin cututtukan nan ba, watakila a iya samun bullar sabbin kwayoyin halittan da za su haifar da bazuwar cututtuka.
A variety of zoonotic CoVs are circulating in the wild.
Yawancin CoV na zoonotic suna yaduwa a cikin daji.
Particularly, bat CoVs with zoonotic potential are so diverse.
Alal misali, cututtukan jemage na CoVs da suka samo asali daga jikin dabbobi suna nan birjik.
There are plenty of opportunities that these zoonotic CoVs evolve and recombine, resulting in the emergence of new CoVs that are more transmissible and/or deadly in humans in future.
Akwai hujjoji da dama da ke nuna cewa cututtukan CoVs suna rayuwa tare da rikida zuwa cutar CoVs da take shafar dan adam cikin sauri kuma ta iya zama mai saurin kisa a nan gaba.
The culture of eating wild animals in some places of China should be abandoned to reduce unnecessary contact between humans and animals.
Ya kamata a watsar da al'adun cin namun daji a wasu wurare na China don rage hulɗa da ba ta dace tsakanin mutane da dabbobi.
With the ordeals of SARS, MERS and COVID-19, a better preparedness and response plan should be in place.
Lura da yadda aka sha fama da cututtukan SARS da MERS da kuma COVID-19, lallai ne a yi shirin kwarai wajen tunkarar ta.
In fact, many viruses have existed in the planet for a very long time.
A zahiri, ƙwayoyin cuta da yawa sun wanzu a cikin duniyar ta dogon lokaci.
They stay in their own natural reservoirs until there is a chance for spillover.
Suna zama a cikin ɗakunan ajiya na asali nasu har sai an sami damar yaduwa.
Although bats have many features that favours the spreading of viruses, the chance for humans to be in contact with bats and other wildlife species can be minimized if people are educated to stay away from them.
Kodayake jemagu suna da fasaloli da yawa waɗanda suka fi dacewa da yada ƙwayoyin cuta, damar da dan Adam zai iya hulɗa da jemagu da sauran nau'in dabbobin daji za a iya rage ta idan an ilmantar da mutane su nisanta da su.
Continuous surveillance in mammals is necessary for better understanding of the ecology of CoVs and their natural hosts, which will prove useful in preventing animal-to-human transmission and future outbreaks.
Cigaba da sanya ido a cikin dabbobi masu shayarwa wajibi ne don kyakkyawar fahimtar yanayin ilimin halittu na CoVs da rundunonin su na halitta, wanda zai tabbatar da amfani wajen hana yaduwar dabbobi zuwa mutane da kuma barkewar gaba.
To conclude, the most effective way to prevent viral zoonosis is for humans to stay away from the ecological niches of the natural reservoirs of the zoonotic viruses.
Hanya mafi sahihanci wajen kare bazuwar cututtuka daga jikin dabbobi zuwa mutane ita ce dan adam ya kaurace wa wadannan dabbobin da suke dauke da kwayoyin cututtukan.
Several pieces in the puzzle of the zoonotic origin of SARS-CoV-2 are still missing.
Abubuwa da yawa a cikin wasan kwaikwayon game da asalin zoonotic na SARS-CoV-2 har yanzu sun ɓace.
First, if bats transmit an ancestral virus of SARS-CoV-2 to pangolins, it will be of interest to see under what circumstances bats and pangolins could share the same ecological niche.
Da farko, idan jemagu suna yada kwayar cutar magabata na SARS-CoV-2 zuwa pangolins, Zai zama abin ban sha'awa idan kaga irin yanayi da jemagu da kuma nau'ikan pangolins za su iya zamowa cikin muhalli iri daya.
Second, if bats play a more direct role in human transmission, how humans get into contact with bats should be determined.
Na biyu kuma, idan dai har jemagu suna taka muhimmiyar rawa wajen yada cutar zuwa mutane, yaya za a tabbatar da haduwar mutum da kuma jemagun.
Third, if a third mammal acts as the true intermediate host, how it interacts with the different species including humans, bats and pangolins has to be clarified.
Na uku, idan dabbobi masu shayarwa na uku suka zama mai masaukin gaskiya na tsakiya, yadda yake ma'amala da nau'ikan halittu gami da mutane, jemagu da pangolins ya zama dole a fayyace su.
Finally, since many mammals including domestic animals might be susceptible to SARS-CoV-2, both surveillance and experimental infection should be conducted.
A karshe dai, lura da galibin dabbobi masu shayarwa ciki har da na gida za su kamuwa da cutar SARS-CoV-2, ya kamata a gudanar da bincike hakika a kai.
Should it be a bat, a pangolin or another mammal, it is expected that SARS-CoV-2 or its parental viruses that are almost identical will be identified in its natural hosts in future.
Shin Jemage ne, ko pangolin ko wata dabba mai shayarwa, ana tsammanin SARS-CoV-2 ko ƙwayoyin mahaifan sa waɗanda suke kusan iri ɗaya ne za a gano shi a cikin masaukinsa na halitta a nan gaba.
Continued investigations in this area will elucidate the evolutionary pathway of SARS-CoV-2 in animals, with important implications in the prevention and control of COVID-19 in humans.
Binciken da aka ci gaba a wannan yankin zai ba da damar hanyar juyin halitta na SARS-CoV-2 a cikin dabbobi, tare da mahimmancin tasiri a cikin rigakafin da kuma sarrafa COVID-19 a cikin mutane.
Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020
Imididdigar Farko na Cigaba da Selectarancin Zaɓaɓɓen Yanayin Lafiya tsakanin Lafiyar masu haƙuri da Cutar Coronavirus 2019 - Amurka, Fabrairu 12-Maris 28, 2020
On March 11, 2020, the World Health Organization declared Coronavirus Disease 2019 (COVID-19) a pandemic.
A ranar 11 ga Maris, 2020, Kungiyar Lafiya ta Duniya ta ayyana cutar Coronavirus 2019 (COVID-19) a matsayin annoba.
As of March 28, 2020, a total of 571,678 confirmed COVID-19 cases and 26,494 deaths have been reported worldwide.
Ya zuwa Maris 28, 2020,an rawaito jimlar 571,678 sun tabbata masu COVID-19 da kuma mutuwar mutane 26,494 a duniya.
Reports from China and Italy suggest that risk factors for severe disease include older age and the presence of at least one of several underlying health conditions.
Rahotanni daga China da Italiya sun nuna cewa dalilai masu haɗari ga mummunar cuta sun haɗa da tsufa da kasancewar aƙalla ɗaya daga cikin yanayin rashin lafiyar da dama.
U.S. older adults, including those aged ≥65 years and particularly those aged ≥85 years, also appear to be at higher risk for severe COVID-19–associated outcomes; however, data describing underlying health conditions among U.S. COVID-19 patients have not yet been reported.
Tsofaffi manyan mutanen U.S., ciki har da waɗanda suna da shekaru daidai ko gaba da 65 da kuma waɗanda suna da manyan shekaru daidai ko gaba da 85, su ma sun bayyana cikin haɗari ga mummunan hadade sakamakon COVID-19; duk da haka, bayanan da ke nuna yanayin cuta wanda ke boye tsakanin marasa lafiyar COVID-19 na U.S. ba a ba da rahoton su ba.
As of March 28, 2020, U.S. states and territories have reported 122,653 U.S. COVID-19 cases to CDC, including 7,162 (5.8%) for whom data on underlying health conditions and other known risk factors for severe outcomes from respiratory infections were reported.
Tun daga Maris 28, 2020, Jihohi da yankuna na U.S. sun ba da rahoton maganganun 122,653 na CVID-19 ga CDC, ciki har da 7,162 (5.8%) wanda bayanan abubuwan da ke tattare da yanayin rashin lafiya da sauran sanannun abubuwan haɗari don mummunan sakamako daga cututtukan numfashi.
Among these 7,162 cases, 2,692 (37.6%) patients had one or more underlying health condition or risk factor, and 4,470 (62.4%) had none of these conditions reported.
Daga cikin waɗannan lamarin cuta 7,162, 2,692 (37.6%) marasa lafiya suna da ɗaya ko sama da ke tattare da wasu cututtuka ko haɗari lamari, da 4,470 (62.4%) basu da waɗannan yanayin da aka ruwaito.
The percentage of COVID-19 patients with at least one underlying health condition or risk factor was higher among those requiring intensive care unit (ICU) admission (358 of 457, 78%) and those requiring hospitalization without ICU admission (732 of 1,037, 71%) than that among those who were not hospitalized (1,388 of 5,143, 27%).
Adadin marasa lafiyar COVID-19 tare da aƙalla mai wata ciwon da ke a boye ko haɗari kamuwa yana da girma tsakanin waɗanda ke sashin buƙatar tsananin kulawar kama gado (ICU) (358 na 457, kashi 78%) da waɗanda ke buƙatar kama gado a asibiti ICU (732 na 1,037, kashi 71%) fiye da wadanda ba su a asibiti (1,388 na 5,143, kashi 27%).
The most commonly reported conditions were diabetes mellitus, chronic lung disease, and cardiovascular disease.
Yawancin yanayin da aka bayar da rahoton su ne mellitus na ciwon sukari, cutar huhu, da cutar zuciya.
These preliminary findings suggest that in the United States, persons with underlying health conditions or other recognized risk factors for severe outcomes from respiratory infections appear to be at a higher risk for severe disease from COVID-19 than are persons without these conditions.
Wadannan binciken na farko sun ba da shawarar cewa a Amurka, mutanen da ke da yanayin rashin lafiya ko kuma wasu halaye masu haɗari don mummunan sakamako daga kamuwa da cututtukan numfashi sun kasance cikin haɗari mafi girma ga mummunan cuta daga COVID-19 fiye da mutane marasa waɗannan yanayin.
Data from laboratory-confirmed COVID-19 cases reported to CDC from 50 states, four U.S. territories and affiliated islands, the District of Columbia, and New York City with February 12–March 28, 2020 onset dates were analyzed.
Bayanai daga dakin gwaje-gwaje na CVID-19 da aka tabbatar wa CDC daga jihohi 50, yankuna hudu na Amurka da tsibirin da ke da alaƙa, Gundumar Columbia, da New York City tare da 12 ga Maris - 28 ga Maris, 2020 kwanakin dabarun fara.
Cases among persons repatriated to the United States from Wuhan, China, and the Diamond Princess cruise ship were excluded.
Damu’oi tsakanin mutanen da aka mayar da su Amurka daga Wuhan, China, da jirgin ruwa mai saukar ungulu irin su Diamond Princess an hana su.
For cases with missing onset dates, date of onset was estimated by subtracting 4 days (median interval from symptom onset to specimen collection date among cases with known dates in these data) from the earliest specimen collection.
Game da kararrakin da ba a fara ba kwanakin farko, an kiyasta ranar farawa da rage 4 kwanakin (tazarar tsakani daga farkon bayyanuwa zuwa samfurin ranar karbawa tsakanin lamura tare da kwanakin da aka sani a cikin waɗannan bayanan) daga farkon samfurin da aka karba.
Public health departments reported cases to CDC using a standardized case report form that captures information (yes, no, or unknown) on the following conditions and potential risk factors: chronic lung disease (inclusive of asthma, chronic obstructive pulmonary disease [COPD], and emphysema); diabetes mellitus; cardiovascular disease; chronic renal disease; chronic liver disease; immunocompromised condition; neurologic disorder, neurodevelopmental, or intellectual disability; pregnancy; current smoking status; former smoking status; or other chronic disease.
Sassan kiwon lafiyar jama'a sun ba da rahoto kamuwa da cuta zuwa CDC ta yin amfani da ingantaccen rahoton wanda ke ɗaukar bayanai (eh, a’a, ko ba a sani ba) a kan waɗannan halaye masu zuwa da abubuwan haɗari masu haɗari: cutar huhu na ƙwaƙwalwa (haɗe da cutar asma, ciwon huhun hanji [COPD], da emphysema); ciwon sukari mellitus; ciwon zuciya; ciwon koda, ciwon hanta na kullum; yanayin immunocompromised; cutar neurologic, neurodevelopment, ko cutar nakasar da hankali; ciki; yanayin shan taba yanzu; mai shan taba a da; ko wasu cututtukan masu tsanani.
Data reported to CDC are preliminary and can be updated by health departments over time; critical data elements might be missing at the time of initial report; thus, this analysis is descriptive, and no statistical comparisons could be made.
Bayanan da aka ba da rahoto ga CDC sune farkon kuma ana iya sabunta su ta sassan kiwon lafiya akan lokaci; mai mahimmancin bayanan zai yiwu a ɓace lokacin rahoton farko; don haka, wannan bincike kwatanci ne, kuma ba za a yi kwatancen ƙididdiga ba.
The percentages of patients of all ages with underlying health conditions who were not hospitalized, hospitalized without ICU admission, and hospitalized with ICU admission were calculated.
kididdigar yawan marasa lafiya na kowane tsararraki tare da yanayin rashin lafiya waɗanda ba su asibiti, asibiti ba tare da shigar da ICU ba, da kuma asibiti tare da shigarwar ICU.
Percentages of hospitalizations with and without ICU admission were estimated for persons aged ≥19 years with and without underlying health conditions.
An kiyasta ƙimar asibiti tare da ba tare da shigar da ICU ba ga mutanen da ke shekara ≥19 tare da kuma ba tare da ƙarancin lafiya ba.
This part of the analysis was limited to persons aged ≥19 years because of the small sample size of cases in children with reported underlying health conditions (N = 32).
Wannan yanki na binciken an iyakance shi ne ga mutanen da ke shekaru kasa da 19 saboda ƙananan samfurin samfurori a cikin yara waɗanda ke da rahoton rashin lafiyar yanayin (N = 32).
To account for missing data among these preliminary reports, ranges were estimated with a lower bound including cases with both known and unknown status for hospitalization with and without ICU admission as the denominator and an upper bound using only cases with known outcome status as the denominator.
Don yin asarar bayanan da suka ɓace tsakanin waɗannan rahotannin farko, an kiyasta jeri yana da ƙananan iyaka ciki har da lokuta tare da yanayin da aka sani da kuma wanda ba a san halin ajiye a asibiti ba tare da ba tare da bada gadon ICU azaman kasa da kuma kan iyaka ta amfani da lamurra tare da sanannu sakamakon matsayi na kasa.
Because of small sample size and missing data on underlying health conditions among COVID-19 patients who died, case-fatality rates for persons with and without underlying conditions were not estimated.
Saboda ƙaramin samfurin ƙira da bayanai da suka ɓace game da yanayin rashin lafiya a tsakanin marasa lafiya na COVID-19 waɗanda suka mutu, ba a ƙididdige ƙididdigar kamuwa da cuta ga mutane da kuma ba tare da yanayin zama ba.
As of March 28, 2020, a total of 122,653 laboratory-confirmed COVID-19 cases (Figure) and 2,112 deaths were reported to CDC.
Tun daga Maris 28, 2020, jimlar kwayoyin cutar 122,653 wadanda aka tabbatar sun kamu da cutar COVID-19 (Figure) da kuma mutuwar mutane 2,112 zuwa CDC.
Case report forms were submitted to CDC for 74,439 (60.7%) cases.
An gabatar da harkar rahoton zuwa CDC don 74,439 kashi (60.7%).
Data on presence or absence of underlying health conditions and other recognized risk factors for severe outcomes from respiratory infections (i.e., smoking and pregnancy) were available for 7,162 (5.8%) patients (Table 1).
Bayanai game da kasancewar ko rashin kasancewar da wasu cututtuka a boye da sauran lamarin haɗari don mummunan sakamako daga samun cutar hanyoyin numfashi (i.e., shan sigari da ciki) sun kasance ga marasa lafiya 7,162 (5.8%) (Tebur 1).
Approximately one third of these patients (2,692, 37.6%), had at least one underlying condition or risk factor.
Kimanin kashi ɗaya bisa uku na waɗannan marasa lafiya kashi (2,692, 37.6%), suna da aƙalla ɗaya cikin yanayin rashin lafiya ko haɗari.
Diabetes mellitus (784, 10.9%), chronic lung disease (656, 9.2%), and cardiovascular disease (647, 9.0%) were the most frequently reported conditions among all cases.
Ciwon sukari mellitus (784, 10.9%), cutar huhu (656, 9.2%), da cututtukan zuciya (647, 9.0%) sune yanayin da aka fi yawan samun rahoton su a cikin dukkan lokuta.
Among 457 ICU admissions and 1,037 non-ICU hospitalizations, 358 (78%) and 732 (71%), respectively occurred among persons with one or more reported underlying health condition.
A cikin yardawar 457 U na ICU da 1,037 marasa aikin asibiti na asibiti, 358 (78%) da 732 (71%), bi da bi sun kasance tsakanin mutane ɗaya ko fiye da aka bayar da rahoton rashin lafiyar.
In contrast, 1,388 of 5,143 (27%) COVID-19 patients who were not hospitalized were reported to have at least one underlying health condition.
A wata bangare, marasa lafiya daga COVID-19 su 1,388 na 5,143 (27%) ba a ajiye su a asibiti ba an ba da rahoton cewa suna da aƙalla wata ciwo a boye guda daya.
Among patients aged ≥19 years, the percentage of non-ICU hospitalizations was higher among those with underlying health conditions (27.3%–29.8%) than among those without underlying health conditions (7.2%–7.8%); the percentage of cases that resulted in an ICU admission was also higher for those with underlying health conditions (13.3%–14.5%) than those without these conditions (2.2%–2.4%) (Table 2).
Daga cikin marasa lafiya masu shekaru ≥19, yawan marasa asibiti na ICU ya fi girma a tsakanin waɗanda ke da yanayin rashin lafiya kashi (27.3% –29.8%) fiye da waɗanda ba tare da mahimmancin yanayin lafiya ba kashi (7.2% –7.8%); da yawan shari'o'in da suka haifar da shigarwar ICU suma sun kasance mafi girma ga waɗanda ke da yanayin rashin lafiya kashi (13.3% –14.5%) fiye da waɗanda ba tare da waɗannan yanayin ba kashi (2.2% –2.4%) (Tebur 2).
Small numbers of COVID-19 patients aged &lt; 19 years were reported to be hospitalized (48) or admitted to an ICU (eight).
kananan lambobin COVID-19 marasa lafiya waɗanda ke da shekaru <19 an ba da rahoton cewa suna asibiti (48) ko shigar da su a cikin ICU (takwas).
In contrast, 335 patients aged &lt; 19 years were not hospitalized and 1,342 had missing data on hospitalization.
A wata bangare, marasa lafiya guda 335 masun shekaru &lt; 19 and kama su gado a asibiti 1,342 ba su da bayanan ko an taba kama su gado cikin asibiti.
Among all COVID-19 patients with complete information on underlying conditions or risk factors, 184 deaths occurred (all among patients aged ≥19 years); 173 deaths (94%) were reported among patients with at least one underlying condition.
A cikin duk marasa lafiya na COVID-19 tare da cikakkun bayanai game da yanayin da ke ciki ko abubuwan haɗari, mutuwar 184 ya faru (duk a cikin marasa lafiya masu shekaru ≥19); An bayar da rahoton mutuwar kashi 173 (94%) a cikin marasa lafiya da ke da matsala ɗaya aƙalla.
Among 122,653 U.S. COVID-19 cases reported to CDC as of March 28, 2020, 7,162 (5.8%) patients had data available pertaining to underlying health conditions or potential risk factors; among these patients, higher percentages of patients with underlying conditions were admitted to the hospital and to an ICU than patients without reported underlying conditions.
Daga cikin rahoton masun kamu da cutar CoVID-19 su 122,653 a U.S. da aka ba da rahoto ga CDC daga Maris 28, 2020, 7,162 kashi (5.8%) marasa lafiya suna da bayanai dangane da yanayin rashin lafiya ko abubuwan da ke haifar da haɗari; a tsakanin wadannan marasa lafiya, mafi girman kashi na marasa lafiya da yanayin da aka shigar a asibiti da kuma wani ICU fiye da marasa lafiya ba tare da rahoton muhimmin yanayin.
These results are consistent with findings from China and Italy, which suggest that patients with underlying health conditions and risk factors, including, but not limited to, diabetes mellitus, hypertension, COPD, coronary artery disease, cerebrovascular disease, chronic renal disease, and smoking, might be at higher risk for severe disease or death from COVID-19.
Wadannan sakamakon sun yi daidai da binciken da aka samu daga China da Italiya, wadanda suka ba da shawarar marasa lafiya da ke tattare da yanayin kiwon lafiya da abubuwan da ke tattare da hadarin, wadanda suka hada da, amma ba a iyakance su ba, da cutar sankarar bargo, hauhawar jini, COPD, cututtukan jijiyoyin zuciya, cututtukan cerebrovascular, cututtukan koda, da shan sigari , na iya kasancewa cikin haɗari mafi girma don cutar mai tsanani ko mutuwa daga COVID-19.
This analysis was limited by small numbers and missing data because of the burden placed on reporting health departments with rapidly rising case counts, and these findings might change as additional data become available.
Wannan ƙididdigar ta iyakance ta ƙananan lambobi da bayanai da suka ɓace saboda nauyin da aka ɗora akan rahoton sassan kiwon lafiya tare da ƙididdigar haɓaka na hanzari, kuma waɗannan binciken na iya canzawa yayin da ƙarin bayanan ya kasance.
It is not yet known whether the severity or level of control of underlying health conditions affects the risk for severe disease associated with COVID-19.
Har yanzu ba a san ko tsananin ko matakin sarrafa yanayin rashin lafiyar ya shafi hadarin kamuwa da cutar mai alaƙa da COVID-19 ba.
Many of these underlying health conditions are common in the United States: based on self-reported 2018 data, the prevalence of diagnosed diabetes among U.S. adults was 10.1%, and the U.S. age-adjusted prevalence of all types of heart disease (excluding hypertension without other heart disease) was 10.6% in 2017.
Yawancin wadannan yanayin rashin lafiyar sun zama ruwan dare a Amurka: dangane da bayanan kai da aka bayar na shekarar 2018, yawan cutar da aka gano a tsakanin manya na Amurka ya kai kashi 10.1%, da kuma yanayin tsufa na Amurka na kowane nau'in cututtukan zuciya (ban da hauhawar jini ba tare da sauran cututtukan zuciya) sun kasance 10.6% a cikin 2017.
The age-adjusted prevalence of COPD among U.S. adults is 5.9%, and in 2018, the U.S. estimated prevalence of current asthma among persons of all ages was 7.9%.
Mamayewar COPD-da-daidaituwa tsakanin tsofaffi na Amurka shine kashi 5.9%, kuma a cikin 2018, ƙididdigar mamayar Amurkawa a halin yanzu na Asma tsakanin mutane a kowane rukunnin shekaru shine kashi 7.9%.
CDC continues to develop and update resources for persons with underlying health conditions to reduce the risk of acquiring COVID-19.
CDC tana ci gaba da haɓaka da sabunta albarkatu ga mutanen da ke da yanayin rashin lafiya don rage haɗarin samun COVID-19.
The estimated higher prevalence of these conditions among those in this early group of U.S. COVID-19 patients and the potentially higher risk for more severe disease from COVID-19 associated with the presence of underlying conditions highlight the importance of COVID-19 prevention in persons with underlying conditions.
Kiyasin kdididdigar mafi girma daga cikin waɗannan yanayin tsakanin waɗanda ke cikin wannan farkon rukunin marasa lafiya na COVID-19 na Amurka da yiwuwar haɗarin mafi girma don ƙarin ciwo mai mahimmanci daga COVID-19 wanda ke haɗuwa da kasancewar yanayin yana nuna mahimmancin rigakafin COVID-19 a cikin mutane yanayin.
The findings in this report are subject to at least six limitations.
Abubuwan da aka samo a cikin wannan rahoto suna ƙarƙashin ƙarancin iyaka shida.
First, these data are preliminary, and the analysis was limited by missing data related to the health department reporting burden associated with rapidly rising case counts and delays in completion of information requiring medical chart review; these findings might change as additional data become available.
Da farko, waɗannan bayanan na farawa ne, kuma binciken ya tsaya domin ɓacewar bayanan da suka shafi sashen kiwon lafiyar wanda ke da nauyin bada rahoton da ya danganci haɓaka tashiwar masu kamuwa da cuta da jinkiri gamawar neman bayanin sake duba hoton ginshiƙi; waɗannan binciken na iya canzawa yayin da ƙarin bayanai suka samu.
Information on underlying conditions was only available for 7,162 (5.8%) of 122,653 cases reported to CDC.
Bayanai game da yanayin da ke ciki sun kasance kawai don 7,162 (5.8%) na 122,653 lokuta da aka ruwaito ga CDC.
It cannot be assumed that those with missing information are similar to those with data on either hospitalizations or underlying health conditions.
Ba za a iya ɗauka cewa waɗanda ke da bayanin ɓoyuwa suna kama da waɗanda ke da bayanai game da ko dai asibiti ko kuma yanayin rashin lafiyar.
Second, these data are subject to bias in outcome ascertainment because of short follow-up time.
Na biyu, wadannan bayanan suna da bambancin ra'ayi ne a game da tabbacin sakamako saboda gajeren lokaci na biyo baya.
Some outcomes might be underestimated, and long-term outcomes cannot be assessed in this analysis.
Wasu sakamakon za a iya raina su, kuma sakamakon binciken na dogon lokaci ba za a iya tantance su a cikin wannan bincike ba.
Third, because of the limited availability of testing in many jurisdictions during this period, this analysis is likely biased toward more severe cases, and findings might change as testing becomes more widespread.
Na uku, saboda karancin gwaji a cikin masarautuka da yawa a cikin wannan lokacin, wannan bincike yana iya zama son kai ga mafi munanan yanayi, kuma binciken zai iya canzawa yayin da gwajin ya yadu.
Fourth, because of the descriptive nature of these data, attack rates among persons with and without underlying health conditions could not be compared, and thus the risk difference of severe disease with COVID-19 between these groups could not be estimated.
Na huɗu, saboda yanayin waɗannan bayanan, yanayin harin a tsakanin mutane tare da ba tare da ƙarancin yanayin kiwon lafiya ba za a iya kwatantawa, kuma ta haka ba za a iya ƙayyade bambancin haɗari na mummunar cuta tare da COVID-19 tsakanin waɗannan rukunin ba.
Fifth, no conclusions could be drawn about underlying conditions that were not included in the case report form or about different conditions that were reported in a single, umbrella category.
Na biyar, ba za a iya yanke shawara game da yanayin da ba a haɗa da su a cikin fan din rahoton ko game da yanayi daban-daban waɗanda aka ruwaito cikin guda ɗaya, rukuni ɗaya.
For example, asthma and COPD were included in a chronic lung disease category.
Misali, maganin fuka da COPD an sanya su a rukunin cututtukan huhu.
Finally, for some underlying health conditions and risk factors, including neurologic disorders, chronic liver disease, being a current smoker, and pregnancy, few severe outcomes were reported; therefore, conclusions cannot be drawn about the risk for severe COVID-19 among persons in these groups.
A ƙarshe, ga wasu halayen kiwon lafiya da dalilai masu haɗari, ciki har da rikicewar neurologic, cututtukan hanta mai tsanani, kasancewa mai shan sigari a yanzu, da juna biyu, 'yan sakamakon mummunan rauni ne aka ruwaito; saboda haka, ba za a iya yanke shawara ba kusantar da hankali game da mumunar haɗarin COVID-19 tsakanin mutane a cikin waɗannan rukunin.
Persons in the United States with underlying health conditions appear to be at higher risk for more severe COVID-19, consistent with findings from other countries.
Mutanen da ke cikin Amurka tare da yanayin rashin lafiya suna bayyana cewa suna cikin haɗarin mai tsananin COVID-19, wanda ke daidai da bincike daga wasu ƙasashe.
Persons with underlying health conditions who have symptoms of COVID-19, including fever, cough, or shortness of breath, should immediately contact their health care provider.
Mutanen da ke da yanayin rashin lafiya waɗanda ke da alamun COVID-19, gami da zazzabi, tari, ko gajeriyar numfashi, yakamata a tuntuɓi mai ba da lafiyarsu nan da nan.
These persons should take steps to protect themselves from COVID-19, through washing their hands; cleaning and disinfecting high-touch surfaces; and social distancing, including staying at home, avoiding crowds, gatherings, and travel, and avoiding contact with persons who are ill.
Wadannan mutane ya kamata su dauki matakai don kare kansu daga COVID-19, ta hanyar wanke hannayensu; tsaftacewa da kuma share manyan hanyoyin tabawa; da kuma nisantar da jama'a, gami da zama a gida, nisantar taron jama'a, haduwa, da tafiye-tafiye, da nisantar cudanya da mutanen da ba su da lafiya.
Maintaining at least a 30-day supply of medication, a 2-week supply of food and other necessities, and knowledge of COVID-19 symptoms are recommended for those with underlying health conditions.
Kula da akalla samar da magunguna na kwanaki 30, wadatar abinci na sati 2 da sauran buƙatu, da kuma sanin alamun COVID-19 ana bada shawarar ga waɗanda ke da yanayin rashin lafiyar.
All persons should take steps to protect themselves from COVID-19 and to protect others.
Duk mutane ya kamata su ɗauki matakai don kare kansu daga COVID-19 kuma don kare wasu.
All persons who are ill should stay home, except to get medical care; should not go to work; and should stay away from others.
Duk mutanen da basu da lafiya ya kamata su kwana a gida, sai dai don samun kulawar likita; kada yaje aiki; kuma ya kamata ya nisanta da wasu.
This is especially important for those who work with persons with underlying conditions or who otherwise are at high risk for severe outcomes from COVID-19.
Wannan yana da mahimmanci musamman ga waɗanda ke aiki tare da mutanen da ke da yanayin rashin ƙarfi ko kuma waɗanda ba haka ba suna cikin haɗari don mummunan sakamako daga COVID-19.
Community mitigation strategies, which aim to slow the spread of COVID-19, are important to protect all persons from COVID-19, especially persons with underlying health conditions and other persons at risk for severe COVID-19–associated disease (https://www.cdc.gov/coronavirus/2019-ncov/downloads/community-mitigation-strategy.pdf).
Dabarun ragewa al'umma aiki, wadanda suke da niyyar rage yaduwar COVID-19, suna da mahimmanci don kare duk mutane daga COVID-19, musamman mutane waɗanda ke da yanayin ciwon da ke boye da sauran mutane waɗanda ke cikin tsananin haɗarin cutar COVID-19 da cutar makamanta (https://www.cdc.gov/coronavirus/2019-ncov/downloads/community-mitigation-strategy.pdf).
What is already known about this topic?
Me aka riga aka sani game da wannan batun?
Published reports from China and Italy suggest that risk factors for severe COVID-19 disease include underlying health conditions, but data describing underlying health conditions among U.S. COVID-19 patients have not yet been reported.
Rahotannin da aka buga daga China da Italiya sun nuna cewa dalilai masu haɗari ga mummunar cutar COVID-19 sun haɗa da ciwon da ke boye a jiki, amma bayanan da ke kwatanta ciwon wanda yake a boye tsakanin masu cutar COVID-19 U.S. ba a ba da rahoto ba.
What is added by this report?
Me aka haɗa da wannan rahoton?
Based on preliminary U.S. data, persons with underlying health conditions such as diabetes mellitus, chronic lung disease, and cardiovascular disease, appear to be at higher risk for severe COVID-19–associated disease than persons without these conditions.
Dangane da bayanan Amurkawa na farko, mutanen da ke da halin rashin lafiya kamar su ciwon sukari mellitus, cututtukan huhu, da cututtukan zuciya, da alama suna cikin haɗari ga mummunan cutar COVID-19-fiye da mutane ba tare da waɗannan yanayin ba.
What are the implications for public health practice?
Menene illolin aikin kiwon lafiyar jama'a?
Strategies to protect all persons and especially those with underlying health conditions, including social distancing and handwashing, should be implemented by all communities and all persons to help slow the spread of COVID-19.
Dabarun da zasu kare duk mutane musamman wadanda ke da matsalar rashin lafiya, gami da nisantar da jama'a da aikin hannu, yakamata a aiwatar da dukkanin al'ummomi da dukkan mutane don taimakawa rage jinkirin yaduwar COVID-19.
Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England
Fitowar wani Sabon Coronavirus (COVID-19): Tsarin Jagorar Fadada Sa Ido da Amfani da Kwalejin Royal na Babban Kwararrun Bincike da Cibiyar Kula da Kulawa da Ingancin Kiwon Lafiyar Jama'a
The Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) and Public Health England (PHE) have successfully worked together on the surveillance of influenza and other infectious diseases for over 50 years, including three previous pandemics.
Kwalejin Royal na Dukanan Kwararru wato (The Royal College of General Practitioners) (RCGP) Cibiyar Binciken Kulawar (RSC) da Ingantacciyar Kula da Lafiyar Jama'a na Ingila (PHE) sun samu nasarar yi aiki tare a kan kula da mura da kuma sauran cututtuka na fiye da shekaru 50, ciki har da uku da suka gabata cututtukan annoba.
With the emergence of the international outbreak of the coronavirus infection (COVID-19), a UK national approach to containment has been established to test people suspected of exposure to COVID-19.
Sakamakon kamuwa da annobar cututtukan coronavirus ta duniya (COVID-19), an kafa tsarin kulawa na ƙasar UK don gwada mutanen da ake zargi da kamuwa da cutar ta COVID-19.
At the same time and separately, the RCGP RSC’s surveillance has been extended to monitor the temporal and geographical distribution of COVID-19 infection in the community as well as assess the effectiveness of the containment strategy.
A lokaci guda kuma daban, an kara fadada RCGP na RC don saka idanu akan sauye da kuma rarraba yanayin cutar COVID-19 a cikin al'umma tare da tantance ingancin dabarun tattara bayanan
The aims of this study are to surveil COVID-19 in both asymptomatic populations and ambulatory cases with respiratory infections, ascertain both the rate and pattern of COVID-19 spread, and assess the effectiveness of the containment policy.
Manufar wannan binciken ita ce bincika COVID-19 a cikin yawan asymptomatic da yanayin ambulatory tare da kamuwa da cututtukan hanyar numfashi, tantance dukan adadin da tsarin yaduwar COVID-19, da kuma samun tasirin tsarin magantarwa.
The RCGP RSC, a network of over 500 general practices in England, extract pseudonymized data weekly.
RCGP RSC, cibiyar sadarwa ce ta ayyukan yau da kullun mai fiye da ayyuka 500 a Ingila, suna fitar da bayanan maganganu masu yawa a mako-mako.
This extended surveillance comprises of five components: (1) Recording in medical records of anyone suspected to have or who has been exposed to COVID-19.
Wannan ƙarin aikin sanya idanu yana kunshe da abubuwa guda biyar: (1) Rikodin a cikin bayanan likitanci na duk wani wanda ake zargi yana da ko ya kamu da cutar ta COVID-19.
Computerized medical records suppliers have within a week of request created new codes to support this.
Masu samar da kayan aikin likitanci na kwamfuta suna da su a cikin sati guda na buƙatar ƙirƙirar sabbin lambobi don tallafawa wannan.
(2) Extension of current virological surveillance and testing people with influenza-like illness or lower respiratory tract infections (LRTI)—with the caveat that people suspected to have or who have been exposed to COVID-19 should be referred to the national containment pathway and not seen in primary care.
(2) Tsawaita aikin binciken barologi na yau da gwaji da kuma gwada mutanen da ke da cutar mura ko ta cuta ta hanji (LRTI) - tare da kwatancen da mutane ke zargin cewa suna da ko sun kamu da COVID-19 ya kamata a koma ga hanyar kawarwa na ƙasa. kuma ba a gan shi a cikin kananun asibiti ba.
(3) Serology sample collection across all age groups.
(3) Samun tarin samfuran Serology a duk tsararraki daban-daban.
This will be an extra blood sample taken from people who are attending their general practice for a scheduled blood test.
Wannan zai zama ƙarin samfurin jini da aka karɓa daga mutanen da suke halarta aikinsu na gwajin jini.
The 100 general practices currently undertaking annual influenza virology surveillance will be involved in the extended virological and serological surveillance.
Ayyukoki 100 na yau da kullun suna gudanar da aikin sa idon shekara na influenza virology za su kasance cikin aikin fadada tsarin binciken sa ido ta virologyl da na serological.
(4) Collecting convalescent serum samples.
(4) tattara samfuran masu warkewa daga serum.
We have the opportunity to escalate the data extraction to twice weekly if needed.
Muna da damar haɓakar hakar bayanan zuwa mako biyu idan an buƙata.
Swabs and sera will be analyzed in PHE reference laboratories.
Za'a bincika Swabs da sera a cikin dakunan gwaje-gwaje na PHE.
General practice clinical system providers have introduced an emergency new set of clinical codes to support COVID-19 surveillance.
Kwararrun masu ba da sabis na asibiti sun gabatar da sabon lamunin gaggawa na lambobin asibiti don tallafawa kulawar COVID-19.
Additionally, practices participating in current virology surveillance are now taking samples for COVID-19 surveillance from low-risk patients presenting with LRTIs.
Bugu da ƙari, ayyukan da ke halartar aikin sa ido na virology yanzu suna ɗaukar samfurori don kulawa ta COVID-19 daga marasa lafiya masu karancin haɗari waɗanda ke gabatar da LRTIs.
Within the first 2 weeks of setup of this surveillance, we have identified 3 cases: 1 through the new coding system, the other 2 through the extended virology sampling.
A tsakanin makonni 2 na farko na saitin wannan sa ido, mun gano mutane 3: 1 ta sabon tsarin lambar, sauran 2 ta hanyar samfurin gwajin barologi da aka fadada.
We have rapidly converted the established national RCGP RSC influenza surveillance system into one that can test the effectiveness of the COVID-19 containment policy.
Munyi saurin canza tsarin RCGP RSC Tsarin kula da mura na kasa a cikin wanda zai iya gwada tasirin ƙa'idar kwantar da COVID-19.
The extended surveillance has already seen the use of new codes with 3 cases reported.
Tsawaita aikin ya riga ya ga yin amfani da sabbin lambobin tare da rahoton 3.
Rapid sharing of this protocol should enable scientific critique and shared learning.
Yin saurin raba wannan yarjejeniya ya kamata ya ba da damar yin amfani da ƙididdigar kimiyya da kuma ilmantarwa mai amfani.
The Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) is a network of general practices (GPs) with a nationally representative population that provides pseudonymized data for weekly surveillance of infectious diseases.
Cibiyar Bincike da Kula da Kulawa da Kulawa da Kulawa (RCGP) na Kwalejin Sarauta na manyana kwararu(RSC) wata hanyar sadarwa ce ta gaba daya (GPs) tare da yawan wakilai a cikin kasar da ke ba da bayanan pseudonymized na sa ido kamuwa na mako-mako.
The disease surveillance program is commissioned by Public Health England (PHE) and covers 37 infectious diseases, including influenza.
Hukumar Kiwon Lafiyar Ingila (PHE) ne ta zartar da tsarin sa ido kan cuta wanda ta kunshi cututtukar mai yaduwa 37, har da cutar mura.
The RCGP RSC and PHE have an established collaboration of over 50 years in influenza and respiratory disease surveillance and are now in their 53rd season of surveillance and analysis.
RCGP RSC da PHE suna da haɗin gwiwar haɗin gwiwa na sama da shekaru 50 a cikin mura da kulawar cututtukan fata kuma yanzu suna cikin shekaru 53 na aikin safiyo da bincike.
The RCGP RSC extracts pseudonymized data from a nationally representative sample of over 500 urban and nonurban GPs each week covering a population of over 4 million.
RCGP RSC ya fitar da bayanan pseudonymized da suka dace daga wakilan kasa baki daya sama da 500 GPs na birni da wadanda ba birrai kowane mako wanda ke kunshe da yawan mutane sama da miliyan 4.
Data from these practices are reported online in a weekly return, which includes monitoring weekly rates of influenza-like illness (ILI) and other communicable and respiratory diseases in England.
Bayanai daga waɗannan al'amuran ana ba da rahoton su ta hanyar yanar gizo a cikin dawowar mako, wanda ya haɗa da saka idanu kan farashin mako-mako na cutar mura (ILI) da sauran cututtukan da ake magana a kai da cututtukan numfashi a Ingila.
We also produce an annual report.
Muna kuma samar da rahoton shekara-shekara.
The RCGP RSC data set includes all coded data and all prescribed items including vaccine exposure.
Saitin bayanan RCGP RSC ya ƙunshi duk lambobin da aka kayyade da duk abubuwan da aka tsara tare da fallasa maganin alurar rigakafi.
The RCGP RSC conducts virology surveillance each influenza season, with 100 GPs participating in the 2019-2020 season (Figure 1).
RCGP RSC tana gudanar da aikin bincike na virology kowane lokacin mura, tare da 100 GPs suna cikin kakar 2019-2020 (Hoto 1).
These virology sampling practices are also recruited to be nationally representative (Figure 1).
Ana kuma ɗaukar waɗannan samfuran virology su zama wakilin ƙasa (Siffa 1).
GPs take nasopharyngeal swabs from persons showing acute respiratory illness within 7 days of the onset of symptoms.
GPs suna ɗaukar samfurin gwaji daga bayan hanci (nasopharyngeal swabs) daga mutanen da ke nuna kamuwa da ciwo hanyar numfashi a cikin kwanaki 7 na bayyanar cututtuka.
Nasopharyngeal swabs are taken from children younger than 5 years showing symptoms of acute bronchitis or bronchiolitis.
Nasopharyngeal swabs ana ɗauka daga yara waɗanda shekarunsu ba su wuce 5 ba suna nuna alamun cutar mashako ko mashako.
Additionally, nasopharyngeal samples are taken from anyone 5 years and older showing acute onset of ILI and respiratory synctial virus.
Bugu da ƙari, ana ɗaukar samfurori na nasopharyngeal daga duk wanda ke da shekaru 5 da haihuwa wanda ya nuna farkon farawar ILI da ƙwayar cuta ta numfashi.
Swabs are tested at the PHE Respiratory Virus Unit for influenza to monitor positivity rates and circulating strains, as well as for measuring vaccine effectiveness.
An gwada Swabs a Sashin Kwayar cuta ta PHE don cutar mura don saka idanu kan yawan cututtukan da ke gudana, da kuma gwargwadon ingancin maganin.
The RCGP RSC successfully conducted a pilot collecting serological samples from adults and linking them to a patient’s medical records during the 2018-2019 influenza season.
RCGP RSC ta sami nasarar gudanar da wani matukin jirgi mai tattara samfuran serological daga manya kuma yana haɗa su zuwa bayanan likitan haƙuri yayin kakar mura ta 2018-2019.
This pilot was in collaboration with the PHE Seroepidemiology Unit and added to the residual blood samples submitted to PHE by National Health Service (NHS) laboratories.
Wannan gwajin farko ya kasance tare da hadin gwiwar PHE Seroepidemiology Unit kuma an kara shi a cikin samfuran jini wanda aka mika wa PHE ta Cibiyar Kiwon Lafiya ta Kasa (NHS).
Serology can provide important information about background population immunity, and sentinel networks can provide a mechanism for systematic data collection and linkage to medical records and health outcomes.
Serology na iya ba da mahimman bayanai game da rigakafin yawan asalin jama'a, kuma cibiyoyin sadarwar aika sakonni na iya samar da hanyoyin tattara bayanai na tsari da haɗin gwiwa ga bayanan likita da sakamakon kiwon lafiya.
The serology pilot has demonstrated the ability of the network to collect serology samples in adults.
Jirgin serology ya nuna ikon cibiyar sadarwa don tara samfuran serology a cikin manya.
With the COVID-19 outbreak, PHE and RCGP RSC have adapted existing influenza surveillance to monitor the spread of COVID-19 in the community, and this protocol sets out the basis for that collaboration.
Tare da barkewar COVID-19, PHE da RCGP RSC sun daidaita yanayin kulawar data kamu don lura da yaduwar COVID-19 a cikin alumma, kuma wannan yarjejeniya ta kafa tushen wannan haɗin gwiwar.
The primary national strategy for COVID-19 infection is containment, with patients who are at high risk managed via the telephone help system NHS111 and the PHE health protection teams, but the RCGP RSC surveillance is entirely separate.
Tsarin dabarun farko na kasa da kasa game da kamuwa da COVID-19 shine ɗaukar hoto, tare da marasa lafiya waɗanda ke cikin haɗari mai yawa ta hanyar sarrafawa ta wayar tarho NHS111 da ƙungiyar kare lafiyar kiwon lafiya ta PHE, amma sa ido RCGP RSC ya kasance daban.